<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine mechanisms by which <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> effect hepatic and extra-hepatic insulin action </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Thirty-one subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomly assigned to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (45 mg) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (2,000 mg) for 4 months </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="105" ids="17234">Glucose</z:chebi> was clamped before and after therapy at approximately 5 mmol/l, insulin raised to approximately 180 pmol/l, C-<z:chebi fb="7" ids="16670">peptide</z:chebi> suppressed with somatostatin, glucagon replaced at approximately 75 pg/ml, and <z:chebi fb="3" ids="17754">glycerol</z:chebi> maintained at approximately 200 mmol/l to ensure comparable and equal portal concentrations on <z:hpo ids='HP_0000001'>all</z:hpo> occasions </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin-induced stimulation of <z:chebi fb="105" ids="17234">glucose</z:chebi> disappearance did not differ before and after treatment with either <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (23 +/- 3 vs. 24 +/- 2 micromol x kg(-1) x min(-1)) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (22 +/- 2 vs. 24 +/- 3 micromol x kg(-1) x min(-1)) </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> enhanced (P &lt; 0.01) insulin-induced suppression of both <z:chebi fb="105" ids="17234">glucose</z:chebi> production (6.0 +/- 1.0 vs. 0.2 +/- 1.6 micromol x kg(-1) x min(-1)) and gluconeogenesis (n = 11; 4.5 +/- 0.9 vs. 0.8 +/- 1.2 micromol x kg(-1) x min(-1)) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> did not alter either suppression of <z:chebi fb="105" ids="17234">glucose</z:chebi> production (5.8 +/- 1.0 vs. 5.0 +/- 0.8 micromol x kg(-1) x min(-1)) or gluconeogenesis (n = 9; 3.7 +/- 0.8 vs. 2.6 +/- 0.7 micromol x kg(-1) x min(-1)) </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin-induced suppression of free fatty acids was greater (P &lt; 0.05) after treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (0.14 +/- 0.03 vs. 0.06 +/- 0.01 mmol/l) but unchanged with <z:chebi fb="0" ids="6801">metformin</z:chebi> (0.12 +/- 0.03 vs. 0.15 +/- 0.07 mmol/l) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Thus, relative to <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> improves hepatic insulin action in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, partly by enhancing insulin-induced suppression of gluconeogenesis </plain></SENT>
<SENT sid="8" pm="."><plain>On the other hand, both drugs have comparable effects on insulin-induced stimulation of <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake </plain></SENT>
</text></document>